학술논문

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
Document Type
Abstract
Source
In Annals of Oncology September 2022 33 Supplement 7:S763-S764
Subject
Language
ISSN
0923-7534